Pharma

Your Article Summary

See Latest Articles

Corcept Therapeutics Announces Negative Results From the Second of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/02/06

Corcept Therapeutics Incorporated announced that the second of its three Phase 3 trials evaluating CORLUX for treating the psychotic features of Psychotic Major Depression (PMD) was negative. Study 09 was a randomized, double-blind, placebo-controlled study

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Amgen, 12/10/09

Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09

 See all of Drug Trials